MSI among the cohort patients
| Pt . | Disease . | Status . | Bulk DNA MSI . | MSI + leukemia (%)* . |
|---|---|---|---|---|
| L1 | AML | Diagnosis | Negative | (2.7) 1/38 |
| L1 | AML | Relapse | Negative | (3.7) 1/27 |
| L2 | AML | Diagnosis | Negative | (2.8) 1/35 |
| L2 | AML | Relapse | Negative | (10.5) 4/38 |
| L3 | ALL | Diagnosis | Negative | (0) 0/29 |
| L3 | ALL | Relapse | Negative | (9.7) 3/31 |
| L4 | ALL | Diagnosis | Negative | (0) 0/18 |
| L4 | ALL | Relapse | Negative | (0) 0/27 |
| L5 | CML blast crisis | Diagnosis | Negative | (2.2) 1/45 |
| L5 | CML blast crisis | Relapse | Negative | (55) 18/33 |
| L6 | AML | Diagnosis | Negative | (6.9) 2/29 |
| Pt . | Disease . | Status . | Bulk DNA MSI . | MSI + leukemia (%)* . |
|---|---|---|---|---|
| L1 | AML | Diagnosis | Negative | (2.7) 1/38 |
| L1 | AML | Relapse | Negative | (3.7) 1/27 |
| L2 | AML | Diagnosis | Negative | (2.8) 1/35 |
| L2 | AML | Relapse | Negative | (10.5) 4/38 |
| L3 | ALL | Diagnosis | Negative | (0) 0/29 |
| L3 | ALL | Relapse | Negative | (9.7) 3/31 |
| L4 | ALL | Diagnosis | Negative | (0) 0/18 |
| L4 | ALL | Relapse | Negative | (0) 0/27 |
| L5 | CML blast crisis | Diagnosis | Negative | (2.2) 1/45 |
| L5 | CML blast crisis | Relapse | Negative | (55) 18/33 |
| L6 | AML | Diagnosis | Negative | (6.9) 2/29 |
MSI indictes microsatellite instability; Pt, patient; AML, acute myeloid leukemia; ALL, acute lymphoblastic leukemia; and CML, chronic myeloid leukemia.
The total number of cells used for the analysis of the percentage of MSI cells was the actual number of cells which underwent successful whole genome amplification (> 25% amplified alleles). Cells that were excluded from the lineage reconstruction were not excluded from the MSI analysis.